Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe

Core Insights - Cryoport, Inc. has opened a new IntegriCell facility in Villers-le-Bouillet, Belgium, aimed at supporting clinical and commercial cell-based therapy programs through advanced cryopreservation solutions for leukapheresis materials [1][3][4] Group 1: Facility Overview - The IntegriCell facility spans approximately 1,300 square meters (about 13,400 square feet) and is GMP-compliant, enhancing Cryoport's capabilities in cryogenic preservation methods for leukapheresis materials [3] - The facility is designed to cryopreserve over 1,100 leukapheresis products annually, ensuring a reliable supply of high-quality, manufacture-ready cryopreserved leukopaks [3][4] Group 2: Strategic Importance - This facility serves as Cryoport Systems' European Center of Excellence, facilitating the transfer of optimized cryopreservation processes to other Cryoport locations, thereby ensuring consistent quality across various clinical and commercial programs [3][4] - The opening of the Belgium facility extends Cryoport's global reach and enhances its ability to deliver standardized cryopreservation solutions, which is critical for the cell therapy community [4] Group 3: Company Background - Cryoport, Inc. is recognized as a global leader in supply chain solutions for the life sciences sector, particularly focusing on cell and gene therapies [5] - The company operates over 50 global locations across 17 countries, providing a broad array of supply chain solutions, including temperature-controlled packaging and specialized bio-logistics services [6]